Graham Larson Barlow

Graham Larson Barlow

Auto-generated profile, based on publicly available information

Graham Larson Barlow

Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in Cell
Verified
Journal Article
Open access
CSChristian Schuerch
Christian Schuerch
SBSalil S. Bhate
Salil S. Bhate
GBGraham L. Barlow
Graham L. Barlow
DPDarci J. Phillips
Darci J. Phillips
LNLuca Noti
Luca Noti
GNGarry P. Nolan
Garry P. Nolan
Antitumoral immunity requires organized, spatially nuanced interactions between components of the immune tumor microenvironment (iTME). Understanding this coordinated behavior in effective versus ineffective tumor control will advance immunotherapies. We re-engineered co-detection by indexing (CODEX) for paraffin-embedded tissue microarrays, enabling simultaneous profiling of 140 tissue regions from 35 advanced-stage colorectal cancer (CRC) patients with 56 protein markers. We identified nine conserved, distinct cellular neighborhoods (CNs)—a collection of components characteristic of the CRC iTME. Enrichment of PD-1+CD4+ T cells only within a granulocyte CN positively correlated with survival in a high-risk patient subset. Coupling of tumor and immune CNs, fragmentation of T cell and macrophage CNs, and disruption of inter-CN communication was associated with inferior outcomes. This study provides a framework for interrogating how complex biological processes, such as antitumoral immunity, occur through concerted actions of cells and spatial domains.

18 November 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
DPDarci Phillips
Darci Phillips
MMMagdalena Matusiak
Magdalena Matusiak
BGBelén Rivero Gutierrez
Belén Rivero Gutierrez
SBSalil S. Bhate
Salil S. Bhate
GBGraham L. Barlow
Graham L. Barlow
GNGarry P. Nolan
Garry P. Nolan
Cutaneous T cell lymphomas (CTCL) are rare but aggressive cancers without effective treatments. While a subset of patients derive benefit from PD-1 blockade, there is a critically unmet need for predictive biomarkers of response. Herein, we perform CODEX multiplexed tissue imaging and RNA sequencing on 70 tumor regions from 14 advanced CTCL patients enrolled in a pembrolizumab clinical trial (NCT02243579). We find no differences in the frequencies of immune or tumor cells between responders and non-responders. Instead, we identify topographical differences between effector PD-1+ CD4+ T cells, tumor cells, and immunosuppressive Tregs, from which we derive a spatial biomarker, termed the SpatialScore, that correlates strongly with pembrolizumab response in CTCL. The SpatialScore coincides with differences in the functional immune state of the tumor microenvironment, T cell function, and tumor cell-specific chemokine recruitment and is validated using a simplified, clinically accessible tissue imaging platform. Collectively, these results provide a paradigm for investigating the spatial balance of effector and suppressive T cell activity and broadly leveraging this biomarker approach to inform the clinical use of immunotherapies.

18 January 2022 in BMC Bioinformatics
Verified
Journal Article
Open access
PDF file
MLMichael Y. Lee
Michael Y. Lee
JBJacob S. Bedia
Jacob S. Bedia
SBSalil S. Bhate
Salil S. Bhate
GBGraham L. Barlow
Graham L. Barlow
DPDarci Phillips
Darci Phillips
CSChristian Schuerch
Christian Schuerch
Background: Algorithmic cellular segmentation is an essential step for the quantitative analysis of highly multiplexed tissue images. Current segmentation pipelines often require manual dataset annotation and additional training, significant parameter tuning, or a sophisticated understanding of programming to adapt the software to the researcher’s need. Here, we present CellSeg, an open-source, pre-trained nucleus segmentation and signal quantification software based on the Mask region-convolutional neural network (R-CNN) architecture. CellSeg is accessible to users with a wide range of programming skills. Results: CellSeg performs at the level of top segmentation algorithms in the 2018 Kaggle Data Challenge both qualitatively and quantitatively and generalizes well to a diverse set of multiplexed imaged cancer tissues compared to established state-of-the-art segmentation algorithms. Automated segmentation post-processing steps in the CellSeg pipeline improve the resolution of immune cell populations for downstream single-cell analysis. Finally, an application of CellSeg to a highly multiplexed colorectal cancer dataset acquired on the CO-Detection by indEXing (CODEX) platform demonstrates that CellSeg can be integrated into a multiplexed tissue imaging pipeline and lead to accurate identification of validated cell populations. Conclusion: CellSeg is a robust cell segmentation software for analyzing highly multiplexed tissue images, accessible to biology researchers of any programming skill level.

6 February 2021 in European Journal of Immunology
Verified
Journal Article
Open access
PDF file
JKJulia Kennedy‐Darling
Julia Kennedy‐Darling
SBSalil S. Bhate
Salil S. Bhate
JHJohn W. Hickey
John W. Hickey
SBSarah Black
Sarah Black
GBGraham L. Barlow
Graham L. Barlow
GNGarry P. Nolan
Garry P. Nolan
Multiparameter tissue imaging enables analysis of cell‐cell interactions in situ, the cellular basis for tissue structure, and novel cell types that are spatially restricted, giving clues to biological mechanisms behind tissue homeostasis and disease. Here, we streamlined and simplified the multiplexed imaging method CO‐Detection by indEXing (CODEX) by validating 58 unique oligonucleotide barcodes that can be conjugated to antibodies. We showed that barcoded antibodies retained their specificity for staining cognate targets in human tissue. Antibodies were visualized one at a time by adding a fluorescently labeled oligonucleotide complementary to oligonucleotide barcode, imaging, stripping, and repeating this cycle. With this we developed a panel of 46 antibodies that was used to stain five human lymphoid tissues: three tonsils, a spleen, and a lymph node. To analyze the data produced, an image processing and analysis pipeline was developed that enabled single‐cell analysis on the data, including unsupervised clustering that revealed 31 cell types across all tissues. We compared cell‐type compositions within and directly surrounding follicles from the different lymphoid organs and evaluated cell‐cell density correlations. This sequential oligonucleotide exchange technique enables a facile imaging of tissues that leverages pre‐existing imaging infrastructure to decrease the barriers to broad use of multiplexed imaging. This article is protected by copyright. All rights reserved

1 July 2022 in Science Advances
Verified
Journal Article
Open access
TSTala Shekarian
Tala Shekarian
CZCarl P. Zinner
Carl P. Zinner
EBEwelina M. Bartoszek
Ewelina M. Bartoszek
WDWandrille Duchemin
Wandrille Duchemin
AWAnna T. Wachnowicz
Anna T. Wachnowicz
GHGregor Hutter
Gregor Hutter
A patient-tailored, ex vivo drug response platform for glioblastoma (GBM) would facilitate therapy planning, provide insights into treatment-induced mechanisms in the immune tumor microenvironment (iTME), and enable the discovery of biomarkers of response. We cultured regionally annotated GBM explants in perfusion bioreactors to assess iTME responses to immunotherapy. Explants were treated with anti-CD47, anti–PD-1, or their combination, and analyzed by multiplexed microscopy [CO-Detection by indEXing (CODEX)], enabling the spatially resolved identification of >850,000 single cells, accompanied by explant secretome interrogation. Center and periphery explants differed in their cell type and soluble factor composition, and responses to immunotherapy. A subset of explants displayed increased interferon-γ levels, which correlated with shifts in immune cell composition within specified tissue compartments. Our study demonstrates that ex vivo immunotherapy of GBM explants enables an active antitumoral immune response within the tumor center and provides a framework for multidimensional personalized assessment of tumor response to immunotherapy.

30 July 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
XRXavier Rovira-Clavé
Xavier Rovira-Clavé
SJSizun Jiang
Sizun Jiang
YBYunhao Bai
Yunhao Bai
BZBokai Zhu
Bokai Zhu
GBGraham Barlow
Graham Barlow
GNGarry P. Nolan
Garry P. Nolan
Simultaneous visualization of the relationship between multiple biomolecules and their ligands or small molecules at the nanometer scale in cells will enable greater understanding of how biological processes operate. We present here high-definition multiplex ion beam imaging (HD-MIBI), a secondary ion mass spectrometry approach capable of high-parameter imaging in 3D of targeted biological entities and exogenously added structurally-unmodified small molecules. With this technology, the atomic constituents of the biomolecules themselves can be used in our system as the “tag” and we demonstrate measurements down to ~30 nm lateral resolution. We correlated the subcellular localization of the chemotherapy drug cisplatin simultaneously with five subnuclear structures. Cisplatin was preferentially enriched in nuclear speckles and excluded from closed-chromatin regions, indicative of a role for cisplatin in active regions of chromatin. Unexpectedly, cells surviving multi-drug treatment with cisplatin and the BET inhibitor JQ1 demonstrated near total cisplatin exclusion from the nucleus, suggesting that selective subcellular drug relocalization may modulate resistance to this important chemotherapeutic treatment. Multiplexed high-resolution imaging techniques, such as HD-MIBI, will enable studies of biomolecules and drug distributions in biologically relevant subcellular microenvironments by visualizing the processes themselves in concert, rather than inferring mechanism through surrogate analyses.